Everest Medicines

What Everest Medicines does

Everest Medicines (HKEX: 1952.HK) is a Shanghai-headquartered biopharmaceutical company founded in 2017 that develops, manufactures, and commercializes innovative therapeutics for patients in Greater China and Asia-Pacific markets. The company operates through a dual-engine model combining in-licensing / business development with proprietary R&D, particularly in its AI+mRNA platform. Three products have reached commercialization: NEFECON (budesonide delayed-release capsules, approved in China November 2023 for IgA nephropathy with NRDL inclusion in November 2024), VELSIPITY (etrasimod arginine tablets, NMPA-approved February 2026 for ulcerative colitis), and XERAVA (eravacycline antibiotic for complicated intra-abdominal infections). The remaining pipeline spans cardiovascular and metabolic (CARDAMYST nasal spray for PSVT, LEROCHOL/lerodalcibep PCSK9 inhibitor, MT1013, Sumecigrel), nephrology (EVER001/civorebrutinib BTK inhibitor, DMX-200), ophthalmology (VIS-101, LNZ100/VIZZ), infectious disease (cefepime-taniborbactam, Bejescin/MIL62), and an mRNA-based oncology franchise (EVM14, EVM16, EVM18).

Revenue is generated through direct commercialization of approved products via hospital and retail pharmacy channels in China and Asia-Pacific, supplemented by upfront payments, milestone payments, and royalties on in- and out-licensing transactions. The proprietary AI+mRNA platform covers the full value chain from antigen design and sequence optimization through a patented LNP delivery system (with a 600+ lipid internal library) to GMP-compliant manufacturing at the Jiashan (Zhejiang) site, which has 58,000 square meters of construction area and capacity of 100 million vials annually. Distribution leverage is being substantially expanded through the 2026 acquisition of Hasten Biopharmaceuticals for USD 250 million, which adds 14 branded chronic disease products and established commercial reach across nine Asia-Pacific geographies including Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines, Hong Kong, Macau, and Taiwan. The company employs 501–1,000 staff across its Shanghai corporate headquarters, Pudong R&D center, and Jiashan manufacturing site, with coverage by major investment banks including Morgan Stanley, Goldman Sachs, Citi, BofA Securities, and CICC.

Name

Everest Medicines

Legal name

Everest Medicines

Website

https://everestmedicines.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Everest Medicines is a Shanghai-headquartered, HKEX-listed biopharmaceutical company that develops and commercializes innovative therapeutics across autoimmune, renal, CKM, ophthalmology, and infectious disease indications for Greater China and Asia-Pacific markets via in-licensing and proprietary AI+mRNA R&D.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Innovative pharmaceutical therapies
• MRNA platform development
• Biopharmaceutical drug development
• Kidney disease treatments
• Cardiovascular metabolic therapies

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Infrastructure, Supply Chain

Revenue model

1. Product Sales: Everest generates revenue through the commercialization of approved pharmaceutical products in Greater China and Asia-Pacific markets. Products include NEFECON (IgA nephropathy), VELSIPITY (ulcerative colitis), and XERAVA (antibiotic).
2. Licensing Revenue - Outbound: Everest receives upfront payments, milestone payments, and royalties from outbound licensing agreements. For example, the Travere Therapeutics deal includes $112.5 million upfront and up to $1.03 billion in milestones plus tiered royalties.
3. Asset Acquisition & Commercialization: Everest acquires rights to develop, manufacture, and commercialize products through asset purchase agreements, paying upfront and milestone payments while retaining commercial rights in licensed territories.
4. In-licensing Agreements: Everest pays upfront payments, milestone payments, and royalties to partners for exclusive rights to develop and commercialize products in Greater China and Asia-Pacific regions.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Everest Medicines discovers, develops, manufactures, and commercializes innovative pharmaceutical products for Greater China and Asia-Pacific markets, with a focus on autoimmune, kidney, cardiovascular/metabolic, infectious disease, and ophthalmology therapeutic areas. The company operates a dual-engine model combining in-house R&D (including an AI+mRNA platform with proprietary LNP delivery technology) with strategic licensing and acquisitions to build its product portfolio. Commercialized products include NEFECON, VELSIPITY, and XERAVA.

Product overview

Everest Medicines operates as an integrated biopharmaceutical company with a portfolio of commercialized products and a proprietary AI+mRNA technology platform. The commercialized products include NEFECON® (IgA nephropathy treatment), VELSIPITY® (ulcerative colitis treatment), and XERAVA® (antibiotic for complicated intra-abdominal infections). The pipeline includes cardiovascular products (CARDAMYST™ nasal spray, LEROCHOL®, Sumecigrel), nephrology products (EVER001/BTK inhibitor, DMX-200, MT1013, Bejescin®), ophthalmology products (VIS-101, LNZ100), and an mRNA technology platform supporting cancer vaccines (EVM14, EVM16) and in vivo CAR-T (EVM18). The company utilizes its A2MS commercialization platform for omnichannel marketing and product lifecycle management.

Differentiator

Problem solved

Functional benefit

Products and services

• NEFECON (budesonide delayed-release capsules) Oral delayed-release budesonide formulation targeting intestinal B cells for treatment of primary IgA nephropathy. Approved by NMPA in November 2023.
• VELSIPITY (etrasimod arginine tablets) Once-daily oral selective S1P receptor modulator for treatment of adults with moderately to severely active ulcerative colitis. Approved by China's NMPA in February 2026.
• XERAVA (eravacycline) Novel fully synthetic fluorocycline intravenous antibiotic for treatment of complicated intra-abdominal infections caused by susceptible Gram-positive, Gram-negative and anaerobic pathogens including MDR isolates.
• CARDAMYST (etripamil) Nasal Spray Rapid-acting calcium channel blocker nasal spray for self-administered treatment of paroxysmal supraventricular tachycardia (PSVT). FDA approved December 2025.
• LEROCHOL (lerodalcibep) Third-generation PCSK9 inhibitor fusion protein for reducing LDL-C in adults with hypercholesterolemia including heterozygous familial hypercholesterolemia. FDA approved December 2025.
• Cefepime-Taniborbactam Fixed dose combination of cefepime with novel beta-lactamase inhibitor taniborbactam for treatment of MDR gram-negative bacterial infections including CRE and carbapenem-resistant Pseudomonas aeruginosa.
• MT1013 First-in-class dual-function peptide targeting Calcium-Sensing Receptor and exerting Osteogenic Growth Peptide effect for treatment of secondary hyperparathyroidism in CKD patients on hemodialysis.
• VIS-101 Novel bispecific fusion protein targeting VEGF-A and Ang-2 for treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.
• EVER001 (civorebrutinib) Next-generation covalent reversible BTK inhibitor in development for treatment of renal diseases including primary membranous nephropathy, FSGS, and minimal change disease.
• EVM14 mRNA Cancer Vaccine Off-the-shelf mRNA-LNP cancer vaccine encoding five tumor-associated antigens for treatment of various squamous cell carcinomas including sq-NSCLC and HNSCC.
• EVM16 Personalized mRNA Cancer Vaccine Personalized mRNA cancer vaccine using proprietary EVER-NEO-1 algorithm for neoantigen prediction, with LNP delivery system for tumor treatment.
• EVM18 In Vivo CAR-T

Quantifiable outcome

• NEFECON achieved over RMB 1 billion sales in first 3 quarters of 2025
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

14 partnerships are on record, tiered minor, major and flagship.

• Hainan HeruiminorStrategic or Co-development Partner · 24 June 2026Commercialization collaboration for Hainan Herui's budesonide enteric capsules approved by NMPA in December 2025. Everest provides technical guidance and quality audits for manufacturing and commercialization.
• DimerixmajorStrategic or Co-development Partner · 16 June 2026Exclusive license agreement for DMX-200, a Phase 3 drug candidate for Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea, and Southeast Asia. Everest paid $10 million upfront with up to $330 million in milestones and 10-15% royalties on net sales.
• Corxel PharmaceuticalsmajorStrategic or Co-development Partner · 8 June 2026Asset Purchase Agreement for LNZ100 (VIZZ) presbyopia treatment in Greater China. Everest acquiring rights from Corxel who previously licensed from LENZ Therapeutics.
• Vcare PharmaTech (Jiangsu)majorStrategic or Co-development Partner · 8 June 2026Exclusive Asia-Pacific licensing agreement for Sumecigrel, a next-generation P2Y12 receptor antagonist for antiplatelet therapy. Everest paid RMB 20 million upfront plus milestone payments.
• Mabworks (Beijing Mabworks Biotech)majorStrategic or Co-development Partner · 4 June 2026Commercialization license agreement for Bejescin (MIL62), a third-generation anti-CD20 monoclonal antibody, across Asia-Pacific. Everest paid RMB 23 million upfront with up to RMB 186 million in sales milestones plus share of gross profit.
• Travere TherapeuticsflagshipStrategic or Co-development Partner · 2 June 2026Exclusive licensing and collaboration agreement for civorebrutinib (EVER001), a BTK inhibitor for rare kidney diseases. Everest received $112.5 million upfront and is eligible for up to $1.03 billion in milestone payments plus tiered royalties. Travere gains rights outside Greater China and certain East/Southeast Asian countries.
• Hasten Biopharmaceuticals (Asia) LimitedflagshipStrategic or Co-development Partner · 8 April 2026Share Purchase Agreement to acquire Hasten Biopharmaceuticals (SG) Pte. Ltd. for USD250 million. The Singapore-based commercial platform holds marketing rights for 14 branded chronic disease products across Asia-Pacific, focusing on cardiovascular and metabolic segments.
• Milestone PharmaceuticalsminorStrategic or Co-development Partner · 25 March 2026Through licensing partner Corxel, Everest acquired Greater China rights for CARDAMYST (etripamil) nasal spray for PSVT treatment.
• Corxel PharmaceuticalsmajorStrategic or Co-development Partner · 23 March 2026Asset Purchase Agreement to develop and commercialize CARDAMYST (etripamil) nasal spray in Greater China. Everest paid $30 million upfront plus up to $20 million in milestones.
• Micot (Shaanxi Micot Pharmaceutical Technology)majorStrategic or Co-development Partner · 5 February 2026Exclusive license agreement for MT1013, a first-in-class dual-targeting receptor agonist polypeptide for secondary hyperparathyroidism. Everest paid RMB 200 million upfront with up to RMB 1,040 million in milestones.
• LIB TherapeuticsmajorStrategic or Co-development PartnerExclusive license rights for LEROCHOL (lerodalcibep), a third-generation PCSK9 inhibitor, in Greater China. LIB received FDA approval in December 2025 and Everest has BLA under NMPA review.
• Venatorx PharmaceuticalsminorStrategic or Co-development PartnerExclusive licensing agreement for cefepime-taniborbactam development in collaboration with Venatorx for treatment of complicated urinary tract infections.
• Kezar Life SciencesminorOthers2023 collaboration with Kezar mentioned in context of Kevin Tang's acquisition activities.
• SinoMab BioScienceminorStrategic or Co-development PartnerPartnership involving EVER001 (XNW1011) BTK inhibitor development, with SinoMab conducting Phase 1 study with healthy subjects in China.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Zai Lab: Zai Lab is a US-headquartered, HKEX-listed biopharma that licenses global innovative therapeutics for development and commercialization in Greater China — nearly identical business model to Everest Medicines, including in-licensing from Western partners, China-led clinical execution, and direct commercialization through a hospital sales force.
• Innovent Biologics: Innovent is a leading Chinese biopharma (HKEX: 1801) developing and commercializing innovative oncology and metabolic drugs, including the successful launch of sintilimab. Comparable to Everest in therapeutic focus (cardiometabolic, immuno-oncology), China/Asia commercial scale, and dual licensing + in-house R&D strategy.
• Hutchmed: Hutchmed (HKEX: 13; NASDAQ: HCM) is a Hong Kong-listed Chinese biopharma developing innovative oncology and immunology drugs with both China and global commercialization. Comparable to Everest in its China-rooted innovation model, multi-asset pipeline, and ambition to build a global specialty pharma presence.
• Akeso, Inc. Akeso (HKEX: 9926) is a Chinese biopharma focused on immuno-oncology bispecifics and antibodies, with a deep pipeline of internally developed innovative biologics. Comparable to Everest as a China-based innovative biopharma scaling innovative therapies with NMPA approvals and global partnership potential.
• Junshi Biosciences: Junshi (HKEX: 1877; SHA: 688180) is a Chinese biopharma focused on innovative antibodies and mRNA-based therapeutics, including toripalimab. Comparable to Everest in pursuing innovative biologic and mRNA modalities with China commercialization plus selective global partnerships.

Broad incumbents

• BeiGene / BeOne Medicines: BeiGene (now BeOne Medicines) is a much larger Chinese biopharma (HKEX: 6160; NASDAQ: ONC) with a globally commercialized oncology portfolio including BRUKINSA. Comparable to Everest as a Chinese-rooted biopharma developing and commercializing innovative therapies globally, but materially larger in scale and more oncology-concentrated.
• Hansoh Pharmaceutical: Hansoh (HKEX: 3692) is one of China's largest innovative pharma companies with a broad portfolio across oncology, CNS, anti-infectives and metabolic disease. Comparable to Everest as a major Chinese innovative pharma with NMPA-approved innovative drugs, but operates at substantially greater scale and with deeper internal R&D.
• CSPC Pharmaceutical Group: CSPC (HKEX: 1093) is a top-tier Chinese pharma with both generic and innovative drug franchises, including oncology and cardiovascular products. Comparable to Everest as a Chinese pharma with cardiovascular and renal therapy presence, though much larger and more diversified.
• Sino Biopharmaceutical: Sino Biopharm (HKEX: 1177) is one of China's largest pharma groups with an extensive innovative drug pipeline across hepatitis, oncology, cardiovascular and respiratory. Comparable to Everest as a large Chinese pharma competing for share in cardiometabolic and autoimmune categories, but with substantially greater scale and a more developed domestic commercial footprint.

Emerging players

• Corxel Pharmaceuticals (formerly Everest Medicines' partner): Corxel is an emerging clinical-stage biopharma developing cardiovascular and cardiometabolic assets (including etripamil/CARDAMYST and LNZ100), which Everest has transacted with as both licensor and licensee. Comparable as a focused Asia-Pacific/China-oriented cardiovascular biopharma operating in the same therapeutic categories Everest is building around.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/everest-medicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Everest Medicines